Brian Chan1,2, Karli Kondo3,4, Michele Freeman3, Chelsea Ayers3, Jessica Montgomery3, Devan Kansagara5,3,6. 1. Division of General Internal Medicine and Geriatrics, Oregon Health & Science University, 3181 SW Sam Jackson Park Road L475, Portland, OR, 97239-3098, USA. chanbri@ohsu.edu. 2. Central City Concern, Portland, OR, USA. chanbri@ohsu.edu. 3. Evidence Synthesis Program Center, VA Portland Health Care System, Portland, OR, USA. 4. Research Integrity Office, Oregon Health & Science University, Portland, OR, USA. 5. Division of General Internal Medicine and Geriatrics, Oregon Health & Science University, 3181 SW Sam Jackson Park Road L475, Portland, OR, 97239-3098, USA. 6. Department of Medicine, VA Portland Health Care System, Portland, OR, USA.
Abstract
BACKGROUND: Currently, there are no accepted FDA-approved pharmacotherapies for cocaine use disorder, though numerous medications have been tested in clinical trials. We conducted a systematic review and meta-analysis to better understand the effectiveness of pharmacotherapy for cocaine use disorder. METHODS: We searched multiple data sources (MEDLINE, PsycINFO, and Cochrane Library) through November 2017 for systematic reviews and randomized controlled trials (RCTs) of pharmacological interventions in adults with cocaine use disorder. When possible, we combined the findings of trials with comparable interventions and outcome measures in random-effects meta-analyses. We assessed the risk of bias of individual trials and the strength of evidence for each outcome using standardized criteria. Outcomes included continuous abstinence (3+ consecutive weeks); cocaine use; harms; and study retention. For relapse prevention studies (participants abstinent at baseline), we examined lapse (first cocaine positive or missing UDS) and relapse (two consecutive cocaine positive or missed UDS'). RESULTS: Sixty-six different drugs or drug combinations were studied in seven systematic reviews and 48 RCTs that met inclusion criteria. Antidepressants were the most widely studied drug class (38 RCTs) but appear to have no effect on cocaine use or treatment retention. Increased abstinence was found with bupropion (2 RCTs: RR 1.63, 95% CI 1.02 to 2.59), topiramate (2 RCTs: RR 2.56, 95% CI 1.39 to 4.73), and psychostimulants (14 RCTs: RR 1.36, 95% CI 1.05 to 1.77), though the strength of evidence for these findings was low. We found moderate strength of evidence that antipsychotics improved treatment retention (8 RCTs: RR 1.33, 95% CI 1.03 to 1.75). DISCUSSION: Most of the pharmacotherapies studied were not effective for treating cocaine use disorder. Bupropion, psychostimulants, and topiramate may improve abstinence, and antipsychotics may improve retention. Contingency management and behavioral interventions along with pharmacotherapy should continue to be explored. SR REGISTRATION: Prospero CRD42018085667.
BACKGROUND: Currently, there are no accepted FDA-approved pharmacotherapies for cocaine use disorder, though numerous medications have been tested in clinical trials. We conducted a systematic review and meta-analysis to better understand the effectiveness of pharmacotherapy for cocaine use disorder. METHODS: We searched multiple data sources (MEDLINE, PsycINFO, and Cochrane Library) through November 2017 for systematic reviews and randomized controlled trials (RCTs) of pharmacological interventions in adults with cocaine use disorder. When possible, we combined the findings of trials with comparable interventions and outcome measures in random-effects meta-analyses. We assessed the risk of bias of individual trials and the strength of evidence for each outcome using standardized criteria. Outcomes included continuous abstinence (3+ consecutive weeks); cocaine use; harms; and study retention. For relapse prevention studies (participants abstinent at baseline), we examined lapse (first cocaine positive or missing UDS) and relapse (two consecutive cocaine positive or missed UDS'). RESULTS: Sixty-six different drugs or drug combinations were studied in seven systematic reviews and 48 RCTs that met inclusion criteria. Antidepressants were the most widely studied drug class (38 RCTs) but appear to have no effect on cocaine use or treatment retention. Increased abstinence was found with bupropion (2 RCTs: RR 1.63, 95% CI 1.02 to 2.59), topiramate (2 RCTs: RR 2.56, 95% CI 1.39 to 4.73), and psychostimulants (14 RCTs: RR 1.36, 95% CI 1.05 to 1.77), though the strength of evidence for these findings was low. We found moderate strength of evidence that antipsychotics improved treatment retention (8 RCTs: RR 1.33, 95% CI 1.03 to 1.75). DISCUSSION: Most of the pharmacotherapies studied were not effective for treating cocaine use disorder. Bupropion, psychostimulants, and topiramate may improve abstinence, and antipsychotics may improve retention. Contingency management and behavioral interventions along with pharmacotherapy should continue to be explored. SR REGISTRATION: Prospero CRD42018085667.
Authors: Adam Bisaga; Efrat Aharonovich; Wendy Y Cheng; Frances R Levin; John J Mariani; Wilfrid N Raby; Edward V Nunes Journal: Drug Alcohol Depend Date: 2010-05-26 Impact factor: 4.492
Authors: Alison Oliveto; James Poling; Michael J Mancino; D Keith Williams; Jeff Thostenson; Rhonda Pruzinsky; Kishorchandra Gonsai; Mehmet Sofuoglu; Gerardo Gonzalez; Shanti Tripathi; Thomas R Kosten Journal: Addiction Date: 2011-10-10 Impact factor: 6.526
Authors: Wilfrid Noel Raby; Eric A Rubin; Fatima Garawi; Wendy Cheng; Ella Mason; Lisa Sanfilippo; Stephanie Lord; Adam Bisaga; Efrat Aharonovich; Frances Levin; David McDowell; Edward V Nunes Journal: Am J Addict Date: 2013-06-26
Authors: Maryam Afshar; Clifford M Knapp; Ofra Sarid-Segal; Eric Devine; Laurie Sickles Colaneri; Lisa Tozier; Megan E Waters; Megan A Putnam; Domenic A Ciraulo Journal: Am J Drug Alcohol Abuse Date: 2012-01-05 Impact factor: 3.829
Authors: Michael J Mancino; Janette McGaugh; Mohit P Chopra; Joseph B Guise; Christopher Cargile; D Keith Williams; Jeff Thostenson; Thomas R Kosten; Nichole Sanders; Alison Oliveto Journal: J Clin Psychopharmacol Date: 2014-04 Impact factor: 3.153
Authors: Landhing M Moran; Karran A Phillips; William J Kowalczyk; Udi E Ghitza; Daniel A Agage; David H Epstein; Kenzie L Preston Journal: Behav Pharmacol Date: 2017-02 Impact factor: 2.293
Authors: Brian D Kiluk; Kathleen M Carroll; Amy Duhig; Daniel E Falk; Kyle Kampman; Shengan Lai; Raye Z Litten; David J McCann; Ivan D Montoya; Kenzie L Preston; Phil Skolnick; Constance Weisner; George Woody; Redonna Chandler; Michael J Detke; Kelly Dunn; Robert H Dworkin; Joanne Fertig; Jennifer Gewandter; F Gerard Moeller; Tatiana Ramey; Megan Ryan; Kenneth Silverman; Eric C Strain Journal: Drug Alcohol Depend Date: 2015-11-21 Impact factor: 4.492
Authors: James Poling; Alison Oliveto; Nancy Petry; Mehmet Sofuoglu; Kishorchandra Gonsai; Gerardo Gonzalez; Bridget Martell; Thomas R Kosten Journal: Arch Gen Psychiatry Date: 2006-02
Authors: Michael Viamonte; Delaram Ghanooni; John M Reynolds; Christian Grov; Adam W Carrico Journal: Curr HIV/AIDS Rep Date: 2022-06-14 Impact factor: 5.495
Authors: Richard Sherva; Congcong Zhu; Leah Wetherill; Howard J Edenberg; Emma Johnson; Louisa Degenhardt; Arpana Agrawal; Nicholas G Martin; Elliot Nelson; Henry R Kranzler; Joel Gelernter; Lindsay A Farrer Journal: Explor Med Date: 2021-02-28
Authors: Robert Suchting; Charles E Green; Constanza de Dios; Jessica Vincent; F Gerard Moeller; Scott D Lane; Joy M Schmitz Journal: Drug Alcohol Depend Date: 2021-09-23 Impact factor: 4.492